Advanced Filters
noise
Found 393 clinical trials
E Emilie Slanoc, RN

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.

18 years of age Female Phase 2
D Dongling Zou, M.D.

The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer

The aim of this trial was to evaluate the efficacy of adjuvant chemotherapy in the locally advanced cervical cancer with residual lesions after concurrent chemoradiation therapy.

18 - 75 years of age Female Phase N/A
N Nimmi Ramanujam, PhD

Pilot Study for Speculum Free Cervical Cancer Screening

The objective of the work described in this protocol is to determine the optical signatures of cervical dysplasia using optical technologies.

21 - 65 years of age Female Phase N/A
M Marie Plante, M.D.

FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment. Patients who receive surgery alone may experience long-term side effects including infertility. The purpose of this research study is to determine whether giving neo-adjuvant chemotherapy prior …

18 - 40 years of age Female Phase N/A
S Shaoxing Sun

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

The goal of this clinical trial is to test a new treatment combination including cadonilimab, anlotinib and granulocyte-macrophage colony-stimulating factor (GM-CSF) in recurrent, metastasis and persistent cervical cancer. The main questions it aims to answer are: The efficacy of this combination in R/M/P CC; The tolerance of this combination in …

18 - 75 years of age Female Phase 2
M Meng Maobin M, MD

Serplulimab for Locally Advanced Cervical Cancer

This study is a randomized, controlled, open-label, phase II clinical trial designed to enroll patients with previously untreated locally advanced cervical cancer. The study aims to evaluate the efficacy and safety of adding chemotherapy to serplulimab combined with concurrent chemoradiotherapy. The primary endpoint of this study is progression-free survival (PFS).

18 - 75 years of age Female Phase 2
C Chun-Chieh Wang Attending Physician, MD PhD

Extended-field Proton Therapy for Cervical Cancer

Severe lymphopenia is a common complication of extended-field radiotherapy in cervical cancer, significantly impacting immune function and clinical outcomes. This study aims to evaluate whether proton therapy, with its superior dose distribution, can reduce lymphopenia and improve survival and toxicity profiles compared to photon therapy.

20 - 85 years of age Female Phase 2/3
M Melissa Knutsen

Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies

This pilot feasibility study evaluates the use of a hyaluronic acid-based spacing gel (Barrigel) in participants with cervical cancer undergoing chemoradiotherapy (chemoRT), including brachytherapy, as part of standard care. The primary goal is to assess feasibility. Other goals include determining whether gel placement can reduce radiation dose to nearby healthy …

18 years of age Female Phase 1
M Martine Francis

A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01

This is a seamless Phase 1/2 study consisting of two components. Phase 1 component is a dose-escalation, single arm, open label study in 10 patients to evaluate the safety and tolerability of KRC 01. Phase 2 component is a randomized, open label, controlled, multi-center study in 60 patients to evaluate …

18 years of age Female Phase 1
S Samsung Medical Center

Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer

This study aims to evaluate the efficacy and safety of hypofractionated intensity-modulated radiation therapy (IMRT) combined with concurrent chemotherapy in patients with cervical cancer. Conventional treatment usually requires 7-8 weeks, which increases the risk of toxicities and treatment delays. This trial seeks to shorten the overall treatment time while maintaining …

20 years of age Female Phase 2

Simplify language using AI